Compare · CMD vs DXCM
CMD vs DXCM
Side-by-side comparison of Cantel Medical Corp. (CMD) and DexCom Inc. (DXCM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CMD and DXCM operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM carries a market cap of $23.76B.
- DXCM has hit the wire 4 times in the past 4 weeks while CMD has been quiet.
- DXCM has more recent analyst coverage (25 ratings vs 0 for CMD).
- Company
- Cantel Medical Corp.
- DexCom Inc.
- Price
- $80.44-1.12%
- $61.55-1.84%
- Market cap
- -
- $23.76B
- 1M return
- -
- -7.89%
- 1Y return
- -
- -13.51%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- n/a
- 2005
- News (4w)
- 0
- 4
- Recent ratings
- 0
- 25
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Latest CMD
- Sanitizing Agents Market Poised for over 7.8% Growth by 2029, Growing by Increasing Investment in The Development of Eco-Friendly Acid-Based Chemicals: States by Exactitude Consultancy
- SEC Form SC TO-I/A filed by Cantel Medical Corp. (Amendment)
- SEC Form SC TO-I/A filed by Cantel Medical Corp. (Amendment)
- SEC Form 15-12B filed by Cantel Medical Corp.
- SEC Form SC 13G filed by Cantel Medical Corp.
- SEC Form 8-K filed by Cantel Medical Corp.
- SEC Form SC TO-I filed by Cantel Medical Corp.
- SEC Form 4 filed by Cantel Medical Corp.
- SEC Form 4 filed by Cantel Medical Corp.
- SEC Form 4 filed by Cantel Medical Corp.
Latest DXCM
- SEC Form 4 filed by Brown Michael Jon
- SEC Form DEFA14A filed by DexCom Inc.
- SEC Form DEF 14A filed by DexCom Inc.
- SEC Form 144 filed by DexCom Inc.
- Dexcom Schedules First Quarter 2026 Earnings Release and Conference Call for April 30, 2026 at 4:30 p.m. Eastern Time
- Amendment: SEC Form SCHEDULE 13G/A filed by DexCom Inc.
- Dexcom upgraded by Evercore ISI with a new price target
- SEC Form 4 filed by Brown Michael Jon
- Dexcom Showcases Breakthrough Outcomes for People With Type 2 Diabetes and Product Roadmap at ATTD 2026
- EVP, Chief Financal Officer Sylvain Jereme M was granted 48,774 shares and covered exercise/tax liability with 18,950 shares, increasing direct ownership by 24% to 153,292 units (SEC Form 4)